Can a PI sign the CTA electronically?

Yes. Electronic signatures are legally binding under the ESIGN Act (15 U.S.C. ch. 96) and UETA in most states when intent and attribution are documented; check for any statutory exceptions that might apply.

Is HIPAA coverage required for eSignature platforms?

If the platform will handle PHI, a Business Associate Agreement is required under HIPAA; ensure the vendor supports a BAA and that technical safeguards meet HIPAA standards.

When is notarization or witness required?

Notarization and witness requirements depend on state law and document type; many jurisdictions do not require notarization for CTAs, but verify state-specific rules before requiring it.

How do I prove signer identity if disputed?

Use platform audit trails that record signer email, IP address, timestamps, and optional multi-factor authentication; for stronger assurance, use identity-proofing or certificate-based signatures.

How long must we retain signed CTAs?

Retention depends on federal and institutional rules: HIPAA requires six years (45 CFR §164.530(j)); financial or tax-related items follow IRS rules; consult institutional policy.

What if a signature is later contested?

Preserve the full audit trail and related communications; an evidentiary record that demonstrates intent, consent, and attribution strengthens enforceability in dispute resolution.

Electronic Signature
Templates
Healthcare
Healthcare CTA for PI Signature

Healthcare CTA for PI Signature

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

Healthcare CTA for PI Signature

Study Identification

Sponsor Name:

Institution / Site:

Principal Investigator:

Study Title:

Protocol Number: IRB/IEC Reference #:

IRB Approval Date:

Study Summary

Brief Description of Investigational Product and Procedures

Investigator Commitments and Certifications

By signing below, the Principal Investigator certifies and agrees to the following material obligations:

1. To conduct the study in accordance with the approved protocol, applicable laws and regulations, and the ethical principles of the Declaration of Helsinki. The Investigator will not deviate from the protocol without prior written approval from the Sponsor and the IRB/IEC except where necessary to eliminate immediate hazards to subjects.

2. To obtain and document informed consent from each subject or legally authorized representative prior to any study-specific procedure, and to maintain original signed consent forms in the study records.

3. To promptly report all Serious Adverse Events (SAEs), unanticipated problems, and safety information to the Sponsor and relevant regulatory authorities in accordance with protocol timelines and applicable law.

4. To permit monitoring, audit, and inspection by the Sponsor and regulatory authorities, and to provide access to source documents and records necessary to verify study conduct and data integrity.

5. To ensure investigational product accountability, storage, handling, and disposal in accordance with the protocol and Sponsor instructions.

6. To disclose relevant financial interests and conflicts of interest and to comply with Sponsor and institutional disclosure policies. Financial interest present: Yes

7. To retain study records, including source documents, regulatory files, and essential documents, for the period required by applicable regulations and Sponsor agreement, and to notify Sponsor prior to destruction if required.

Participant Information (for Enrollment Records)

Participant Name Date of Birth Gender Address Phone Emergency Contact (Name, Relationship, Phone)

Insurance & Billing

Insurance Provider Policy / ID Number Group Number Subscriber Name

Medical History

Current Medications Allergies (include drug, food, environmental) Prior Surgeries / Hospitalizations Chronic Conditions / Diagnoses

HIPAA Authorization and Data Use

The Participant (or legally authorized representative) authorizes the use and disclosure of Protected Health Information (PHI) as necessary for the conduct of the study, safety reporting, monitoring, and regulatory compliance. Authorization permits release of study data to Sponsor, monitors, auditors, and regulatory authorities in accordance with applicable law.

This authorization expires on:

Participant authorizes use of PHI: Yes Decline

Publication, Confidentiality, and Data Ownership

The Investigator acknowledges that data generated under this study are the property of the Sponsor and will be handled in accordance with the confidentiality provisions of the CTA. Publication or public presentation of study data shall require prior review and reasonable opportunity for Sponsor comment consistent with the CTA.

Termination and Withdrawal

Either party may terminate the Investigator's participation in the study in accordance with the CTA. Subjects retain the right to withdraw consent and discontinue participation at any time without penalty. The Investigator will notify Sponsor promptly of subject withdrawals and follow requirements for data disposition.

Signatures

Principal Investigator:

By:

Date:

Sponsor / Institution Representative:

By:

Date:

What the Healthcare CTA for PI Signature Is

The Healthcare CTA for PI Signature is a clinical-trial authorization or institutional agreement template used to document a principal investigator's approval, responsibilities, and institution-level commitments for a research study. It typically records the study title, protocol identifier, sponsor and site obligations, patient data handling, and signature blocks for the PI and authorized institutional signatories, and serves as both project-level consent and a contractual record required by institutional review boards, sponsors, and regulatory authorities.

Why a Clear CTA Matters for PI Signatures

A consistent Healthcare CTA for PI Signature centralizes responsibilities, documents data-protection and subject-consent duties, and creates an auditable record for IRB and sponsor review. Clear CTAs reduce ambiguity about who controls PHI, who manages adverse event reporting, and which state or federal rules apply.

Who typically prepares, signs, or reviews this CTA

Typical users span clinical teams, institutional officials, and study sponsors; each role has specific review and signature responsibilities.

Principal Investigators and clinical research staff who verify protocol adherence and patient-safety commitments.
Institutional official signatories (e.g., research administration) who accept institutional liability and resource commitments.
Sponsors and contract managers who confirm funding, indemnity, and data-use terms before site activation.

Confirm role-based approval flow before execution to prevent delays with IRB clearance or sponsor acceptance.

Primary signer profiles

Principal Investigator

The PI is the clinical lead responsible for patient safety, protocol compliance, and accurate reporting of adverse events. The PI’s signature documents acceptance of duties and confirms that study conduct meets IRB-approved procedures and applicable regulations.

Authorized Institutional Signatory

An institutional official (e.g., research admin or sponsored programs officer) signs to bind the institution to budgetary, indemnity, and data-handling commitments and to accept responsibility for institutional-level compliance.

Essential data elements to include

Study Identifier: Protocol ID

PI Name: Full legal name

Institution: Legal entity name

PHI Scope: Types of protected data

Effective Date: MM/DD/YYYY

Signature Method: eSignature type

Step-by-step: completing the CTA for PI signature

Follow a consistent sequence: prepare, verify, route, and archive to ensure IRB and sponsor acceptance.

01

Prepare the document: Insert protocol ID, study title, and contact details.
02

Verify fields: Confirm PI name, institutional signatory, and effective date.
03

Route for signatures: Send to PI first, then institutional signatory and sponsor.
04

Archive record: Store signed copy with audit trail and retention tags.

How to configure an online signing workflow

Set up role-based routing, signer authentication, and field requirements before sending to ensure a compliant flow.

Field	Configuration
Authentication	Email link or SMS code; consider stronger ID for sensitive records
Routing Order	PI first, institutional signatory second, sponsor third
Required Fields	Mark signature, date, and protocol ID as mandatory
Audit Trail	Capture timestamp, IP, and signer attribution

Digital signing and technical delivery options

Choose a platform that supports secure eSigning, audit trails, and integrations with your record systems.

File formats: PDF, DOCX supported
Integrations: Salesforce, NetSuite, Google Workspace
Security: TLS 1.2/1.3; AES-256 at rest

Where to send the signed CTA and common routing destinations

Determine destination copies needed by stakeholders and regulatory records before initiating signatures.

Institutional Records: Upload final signed copy to research administration repository
IRB Office: Provide the signed agreement for the active study file
Sponsor: Send signed copy to study sponsor or contract manager
Principal Investigator: Retain a personal copy for clinical records

Common mistakes to avoid when preparing the CTA

Using informal or abbreviated institution names that do not match contracting records, causing verification delays and potential re-execution.
Leaving protocol ID, effective date, or PI name blank, which prevents linking the CTA to the study registry and monitoring activities.
Failing to document PHI scope and data-use terms clearly, which can trigger HIPAA concerns or require amendment.
Routing out of order or missing required institutional signatures, which can invalidate sponsor acceptance or delay site activation.

Penalties and compliance risks to be aware of

HIPAA Breach: Civil/criminal penalties

IRB Noncompliance: Study suspension risk

Contract Breach: Financial liability

Data Misuse: Regulatory sanctions

Signature Dispute: Legal challenge potential

Recordkeeping Failure: Audit findings

Key timing considerations and typical deadlines

Track IRB, sponsor, and regulatory timing to avoid delays in enrollment and reporting obligations.

IRB Approval Requirement:

IRB approval must be obtained before subject enrollment.

Sponsor Execution:

Sponsor acceptance required before site activation.

Effective Date:

Effective date governs study start and reporting clocks.

Adverse Event Reporting:

Follow sponsor and FDA timelines for serious events.

Contract Amendments:

Execute amendments promptly to remain compliant.

Representative eSignature vendor comparison for CTA execution

Compare common plan criteria for eSignature platforms when selecting a solution for Healthcare CTAs; signNow is listed first per vendor comparison conventions.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Varies by vendor	Varies by vendor	Varies by vendor	Varies by vendor
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No

Frequently asked questions about the Healthcare CTA for PI Signature

Answers address common execution, legal, and technical concerns for PI signatures and electronic workflows.

Need help? Contact support

Can a PI sign the CTA electronically?
Yes. Electronic signatures are legally binding under the ESIGN Act (15 U.S.C. ch. 96) and UETA in most states when intent and attribution are documented; check for any statutory exceptions that might apply.
Is HIPAA coverage required for eSignature platforms?
If the platform will handle PHI, a Business Associate Agreement is required under HIPAA; ensure the vendor supports a BAA and that technical safeguards meet HIPAA standards.
When is notarization or witness required?
Notarization and witness requirements depend on state law and document type; many jurisdictions do not require notarization for CTAs, but verify state-specific rules before requiring it.
How do I prove signer identity if disputed?
Use platform audit trails that record signer email, IP address, timestamps, and optional multi-factor authentication; for stronger assurance, use identity-proofing or certificate-based signatures.
How long must we retain signed CTAs?
Retention depends on federal and institutional rules: HIPAA requires six years (45 CFR §164.530(j)); financial or tax-related items follow IRS rules; consult institutional policy.
What if a signature is later contested?
Preserve the full audit trail and related communications; an evidentiary record that demonstrates intent, consent, and attribution strengthens enforceability in dispute resolution.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now